Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African Adults
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
RATIONALE: Tuberculosis (TB) is a major cause of morbidity and mortality worldwide, thus there is an urgent need for novel TB vaccines. OBJECTIVES: We investigated a novel TB vaccine candidate, M72/AS01, in a phase IIa trial of bacille Calmette-Guérin-vaccinated, HIV-uninfected, and Mycobacterium tuberculosis (Mtb)-infected and -uninfected adults in South Africa. METHODS: Two doses of M72/AS01 were administered to healthy adults, with and without latent Mtb infection. Participants were monitored for 7 months after the first dose; cytokine production profiles, cell cycling, and regulatory phenotypes of vaccine-induced T cells were measured by flow cytometry. MEASUREMENTS AND MAIN RESULTS: The vaccine had a clinically acceptable safety profile, and induced robust, long-lived M72-specific T-cell and antibody responses. M72-specific CD4 T cells produced multiple combinations of Th1 cytokines. Analysis of T-cell Ki67 expression showed that most vaccination-induced T cells did not express Th1 cytokines or IL-17; these cytokine-negative Ki67(+) T cells included subsets of CD4 T cells with regulatory phenotypes. PD-1, a negative regulator of activated T cells, was transiently expressed on M72-specific CD4 T cells after vaccination. Specific T-cell subsets were present at significantly higher frequencies after vaccination of Mtb-infected versus -uninfected participants. CONCLUSIONS: M72/AS01 is clinically well tolerated in Mtb-infected and -uninfected adults, induces high frequencies of multifunctional T cells, and boosts distinct T-cell responses primed by natural Mtb infection. Moreover, these results provide important novel insights into how this immunity may be appropriately regulated after novel TB vaccination of Mtb-infected and -uninfected individuals. Clinical trial registered with www.clinicaltrials.gov (NCT 00600782).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 2×
“Importantly, this PD-1–mediated inhibitory mechanism was apparent in T cells activated in vitro and PD-1 T cells generated in vivo (38).”
BackgroundTransient expression of FOXP3 in human activated nonregulatory CD4 + T cells
Wang, J., Ioan‐Facsinay, A., van der Voort, E. I. H., Huizinga, T. W. J., & Toes, R. E. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636435 · Cited by 1,011 · cited 1×
“However, induction of Foxp3 expression after TCR cross-linking in vitro has been associated with attenuation of effector functions (30), and previous studies have indicated Foxp3 can regulate T-cell activation by inhibiting nuclear factor of activated T cells–mediated transcription (31, 32).”
BackgroundHuman Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines
Miller, J. D., van der Most, R. G., Akondy, R. S., Glidewell, J. T., Albott, S., Masopust, D., Murali-Krishna, K., Mahar, P. L., Edupuganti, S., Lalor, S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.020 · Cited by 601 · cited 4×
“PD-1 was transiently expressed at high levels on M72-specific CD4 T cells 7 days after each vaccination, consistent with transient PD-1 expression on virus-specific CD8 T cells in previous studies in humans vaccinated with either YFV or smallpox vaccines (21, 37).”
ResultInfluentialDuhen, T., Duhen, R., Lanzavecchia, A., Sallusto, F., & Campbell, D. J. (2012) · Blood · doi:10.1182/blood-2011-11-392324 · Cited by 413
Cited by
Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Tait, D. R., Hatherill, M., Van Der Meeren, O., Ginsberg, A. M., Van Brakel, E., Salaun, B., Scriba, T. J., Akite, E. J., Ayles, H. M., Bollaerts, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909953 · Cited by 605
Self-citationPhase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis
Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., Ayles, H. M., Henostroza, G., Thienemann, F., Scriba, T. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1803484 · Cited by 413
Self-citationT cells and adaptive immunity to Mycobacterium tuberculosis in humans
Jasenosky, L. D., Scriba, T. J., Hanekom, W. A., & Goldfeld, A. E. (2015) · Immunological Reviews · doi:10.1111/imr.12274 · Cited by 362
Self-citationThe status of tuberculosis vaccine development
Schrager, L. K., Vekemens, J., Drager, N., Lewinsohn, D. M., & Olesen, O. F. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30625-5 · Cited by 196
Tuberculosis Vaccines and Prevention of Infection
Hawn, T. R., Day, T. A., Scriba, T. J., Hatherill, M., Hanekom, W. A., Evans, T. G., Churchyard, G. J., Kublin, J. G., Bekker, L.-G., & Self, S. G. (2014) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00021-14 · Cited by 164
Self-citation
Metadata
- Authors
- Day, C. L., Tameris, M., Mansoor, N., van Rooyen, M., de Kock, M., Geldenhuys, H., Erasmus, M., Makhethe, L., Hughes, E. J., Gelderbloem, S., Bollaerts, A., Bourguignon, P., Cohen, J., Demoitié, M.-A., Mettens, P., Moris, P., Sadoff, J. C., Hawkridge, A., Hussey, G. D., Mahomed, H., Ofori-Anyinam, O., & Hanekom, W. A.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-15
- Volume
- 188
- Issue
- 4
- Pages
- 492-502
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2108696062
- Cited by
- 120
- References
- 5
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.